309 related articles for article (PubMed ID: 28314859)
1. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
Millar JS; Lassman ME; Thomas T; Ramakrishnan R; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Wagner JA; Holleran S; Obunike J; Liu Y; Aoujil S; Standiford T; Gutstein DE; Ginsberg HN; Rader DJ; Reyes-Soffer G
J Lipid Res; 2017 Jun; 58(6):1214-1220. PubMed ID: 28314859
[TBL] [Abstract][Full Text] [Related]
2. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
3. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
[TBL] [Abstract][Full Text] [Related]
4. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Cohn JS; Wilson A; Wolfe ML; Nartsupha C; Schaefer PM; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
J Lipid Res; 2008 Mar; 49(3):543-9. PubMed ID: 18033754
[TBL] [Abstract][Full Text] [Related]
5. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
[TBL] [Abstract][Full Text] [Related]
6. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
7. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
[TBL] [Abstract][Full Text] [Related]
8. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
Millar JS; Reyes-Soffer G; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Pollan L; Tohyama J; Johnson-Levonas AO; Wagner JA; Holleran S; Obunike J; Liu Y; Ramakrishnan R; Lassman ME; Gutstein DE; Ginsberg HN; Rader DJ
J Clin Invest; 2015 Jun; 125(6):2510-22. PubMed ID: 25961461
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
[TBL] [Abstract][Full Text] [Related]
10. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
[TBL] [Abstract][Full Text] [Related]
11. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
12. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
Page MM; Hooper AJ; Burnett JR
Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
[TBL] [Abstract][Full Text] [Related]
13. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
14. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.
Cohn JS; Patterson BW; Uffelman KD; Davignon J; Steiner G
J Clin Endocrinol Metab; 2004 Aug; 89(8):3949-55. PubMed ID: 15292332
[TBL] [Abstract][Full Text] [Related]
15. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Miyares MA; Davis K
Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
[TBL] [Abstract][Full Text] [Related]
17. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
[TBL] [Abstract][Full Text] [Related]
18. Fate of apolipoproteins C-1, C-iii, and E during lipolysis of human very low density lipoproteins in vitro.
Tam SP; Dory L; Rubinstein D
J Lipid Res; 1981 May; 22(4):641-51. PubMed ID: 7276737
[TBL] [Abstract][Full Text] [Related]
19. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms.
Evans AJ; Sawyez CG; Wolfe BM; Connelly PW; Maguire GF; Huff MW
J Lipid Res; 1993 May; 34(5):703-17. PubMed ID: 8509711
[TBL] [Abstract][Full Text] [Related]
20. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan DC; Watts GF; Nguyen MN; Barrett PH
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
